Arrivent (AVBP) news
Recent news
Arrivent Biopharma, Inc.: H.C. Wainwright raises target price to $47 from $44
H.C. Wainwright has raised its price target for ArriVent Biopharma, Inc. (NASDAQ: AVBP) to $47 from $44, while maintaining a Buy rating . The adjustment reflects the firm’s increased confidence in the potential success of ArriVent’s Phase 3 Alpacca trial for firmonertinib in PACC-mutated non-small…
AInvest Wire · Aug 17, 2026ImportantArriVent BioPharma Shares Rise 21% on Nasdaq Debut
ArriVent BioPharma Shares Rise 21% on Nasdaq Debut On February 23, ArriVent BioPharma made its debut on the Nasdaq stock exchange, raising $175 million through the sale of 9.7 million shares at $18 per share [1]. This marked the second IPO of the year for a biotech company, following CG Oncology's…
AInvest Wire · Jan 26, 2024Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.